ArticleJACC. Case reports2026
Chemotherapy-Induced Arrhythmogenic Right Ventricular Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic and miRNA-Target Pathway Analysis of the DLK1-DIO3 Imprinted microRNA Cluster in Chronic Lymphocytic Leukemia.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder characterized by fibrofatty replacement of the right ventricular myocardium. Anthracycline-induced cardiotoxicity typically manifests as left ventricular dysfunction; however, we present a unique case of an acquired ARVC phenotype secondary to anthracycline chemotherapy exposure. CASE SUMMARY: A 74-year-old man developed recurrent exertional syncope 8 months after completing rituximab, cyclophosphamide, hydroxydaunorubicin (an anthracycline that is also known as doxorubicin), oncovin, and prednisone chemotherapy. He met 3 major 2010 Revised Task Force Criteria for definite ARVC, despite negative genetic testing and absence of family history. He underwent dual-chamber implantable cardioverter-defibrillator implantation with complete resolution of syncopal episodes. DISCUSSION: Recognition of acquired ARVC after anthracycline exposure broadens the spectrum of chemotherapy-related cardiomyopathies and calls for vigilance in patients with unexplained right ventricular dysfunction or arrhythmias after chemotherapy. TAKE-HOME MESSAGES: Anthracyclines may cause isolated right ventricular dysfunction mimicking ARVC. Clinicians should maintain vigilance for right ventricular dysfunction or arrhythmias in patients after anthracycline therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.